1 |
Lea, A. P. and McTavish, D. (1997). Atrovastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 53, 828-847.
DOI
|
2 |
Lennernas, H. (2003). Clinical pharmacokinetics of atrovastatin. Clin. Pharmacokinet. 42, 1141-1160.
DOI
|
3 |
Wacher, V. J., Salphati, L. and Benet, L. Z. (2001). Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. 46, 89-102.
DOI
|
4 |
Wang, E. J., Casciano, C. N., Clement, R. P. and Johnson, W. W. (2000). Two transport binding sites of P-glycoprotein are unequal yet contingent: initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence. Biochim. Biophys. Acta. 1481, 63-74.
DOI
ScienceOn
|
5 |
Graham, D. J., Dow, R. J., Hall, D. J., Alexander, O. F., Mroszczak, E. J. and Freedman, D. (1985). The metabolism and pharmacokinetics of nicardipine hydrochloride in man. Br. J. Cli. Pharmacol. 1, 23-28.
|
6 |
Azie, N. E., Brater, D. C., Becker, P. A., Jones, D. R. and Hall, S. D. (1998). The interaction of diltiazem with lovastatin and pravastatin. Clin. Pharmacol. Ther. 64, 369-377.
DOI
|
7 |
Choi, D. H., Chang, K. S., Hong, S. P. and Choi, J. S. (2008). Effect of atrovastatin on intravenous and oral pharmacokinetics of verapamil in rats. Biopharm. Drug Dispos. 29, 45-50.
DOI
|
8 |
Choi, J. S., Piao, Y. J. and Han, H. K. (2006). Phatmacokinetics interaction between fluvastatin and diltiazem in rats. Biopharm. Drug Dispos. 27, 437-441.
DOI
|
9 |
Cummins, C. L., Jacobsen, W. and Benet, L. Z. (2002). Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 300, 1036-1045.
DOI
|
10 |
Doppenschmitt, S., Spahn-Langguth, H., Rerardh, C. G. and Langguth, P. (1999). Role of P-glycoprotein-mediated secretion in aborptive drug permeability: an approach using passive membrane permeability and affinity to P-glycoprotein. J. Pharm. Sci. 88, 1067-1072.
DOI
|
11 |
Guengerich, F. P. (1991). Reactions and significance of cytochrome P-450 enzymes. J. Biol. Chem. 266, 10019-10022.
|
12 |
Guengerich, F. P., Martin, M. V., Beaune, P. H., Kre-mers, P., Wolff, T. and Waxman, D. J. (1986). Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261, 5051-5060.
|
13 |
Higuchi, S. and Shiobara, Y. (1980). Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. Xenobiotica 10, 889-896.
DOI
|
14 |
Benet, L. Z., Cummins, C. L. and Wu, C. Y. (2003). Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab. 4, 393-398.
DOI
|
15 |
Kolars, J. C., Schmiedlin-Ren, P., Schuetz, J. D., Fang, C. and Watkins, P. B. (1992). Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90, 1871-1878.
DOI
|
16 |
Hysing, E. S., Chelly, J. E., Doursout, M. F., Hartley, C. and Merin, R. G. (1986). Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. Nicardipine and isoflurane. Anaesthesiology 65, 385-391.
DOI
|
17 |
Kaminsky, L. S. and Fasco, M. J. (1991). Small intestinal cytochromes P450. Crit. Rev. Toxicol. 21, 407-422.
DOI
|
18 |
Kishi, Y., Okumura, F. and Furuya, H. (1984). Haemodynamic effects of nicardipine hydrochloride. Studies during its use to control acute hypertension in anaesthetized patients. Br. J. Anaesth. 56, 1003-1007.
DOI
|
19 |
Eastwood, R. J., Galustian, C., Bhamra, R. K. and Holt, D. W. (1990). High-performance liquid chromatographic method for the measurement of nicardipine in plasma or serum. J. Chromatogr. 530, 463-468.
DOI
|
20 |
Graham, D. J., Dow, R. J., Freedman, D., Mroszczak, E. and Ling, T. (1984). Pharmacokinetics of nicardipine following oral and intravenous administration in man. Postgrad. Med. J. 4, 7-10.
|
21 |
Van Swieten, P. A., Hansson, L. and Epstein, M. (1997). Slowly acting calcium antagonists and their merits. Blood Press 6, 78-90.
DOI
|
22 |
Mousa, O., Brater, D. C., Sunblad, K. J. and Hall, S. D. (2000). The interaction of diltiazem with simvastatin. Clin. Pharmacol. Ther. 67, 267-274.
DOI
|
23 |
Saeki, T., Ueda, K., Tanigawara, Y., Hori, R. and Komano, T. (1993). P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Lett. 324, 99-102.
DOI
|
24 |
Shitara, Y. and Sugiyama, Y. (2006). Pharmacokinetics and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interaction and interindixidual differences in transporter and metabolic enzyme function. Pharmacol. 112, 71-105.
|
25 |
Holtzman, C. W., Wiggins, B. S. and Spinler, S. A. (2006). Role of P-glycoprotein in statin drug interaction. Pharmacotherapy 26, 1601-1607.
DOI
|
26 |
Hu, Y. P., Chapey, C. and Robert, J. (1996). Relationship between the inhibition of azidopine binding to P-glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation. Cancer Lett. 109, 203-209.
DOI
|